The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Welcome to MOLECULAR IMAGING AND BIOLOGY, an esteemed journal published by SPRINGER that delves into the rapidly advancing fields of molecular imaging and its applications in biology, with a strong emphasis on cancer research, oncology, and radiology. With ISSN 1536-1632 and E-ISSN 1860-2002, this journal has established itself as a prominent platform for disseminating insightful research and innovative methodologies since its inception in 2002. As of 2023, it holds commendable rankings in notable categories—Q3 in Cancer Research, Q2 in Oncology, and Q2 in Radiology, Nuclear Medicine, and Imaging—illustrating its impact and relevance in these disciplines. Furthermore, with impressive Scopus rankings placing it in the top quartile of journals within its categories, it serves as an essential resource for researchers, professionals, and students seeking to stay informed about the latest developments in molecular imaging technologies and biological applications. While currently not an Open Access journal, the rigorous peer-review process ensures high-quality and impactful contributions to the field, making it a valuable addition to any academic library.

INTERNATIONAL JOURNAL OF LEGAL MEDICINE, published by SPRINGER, stands at the forefront of research in the fields of legal medicine, pathology, and forensic science. With an ISSN of 0937-9827 and an E-ISSN of 1437-1596, this esteemed journal has successfully maintained its reputation as a leading publication since its inception in 1990, providing a platform for the dissemination of cutting-edge research and case studies. The journal is recognized as a Q1 category publication in the 2023 Pathology and Forensic Medicine quartiles, ranking #44 out of 208 in its category on Scopus, reflecting its significant contribution to the academic community—demonstrated by its impressive 79th percentile. While the journal operates under a traditional subscription model, it is committed to enhancing access to critical insights in legal medicine. The INTERNATIONAL JOURNAL OF LEGAL MEDICINE invites researchers, professionals, and students to explore its manuscripts that shed light on the intersection of law and medicine, thus pushing the boundaries of what is known in these vital fields.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

The Journal of Pathology Clinical Research is a prestigious academic platform published by WILEY, dedicated to advancing the field of pathology and forensic medicine. Since its inception in 2015, this Open Access journal has championed the dissemination of cutting-edge research relevant to both clinical practice and laboratory science, allowing for greater visibility and accessibility to researchers, professionals, and students worldwide. With a robust Q1 ranking in the Pathology and Forensic Medicine category for 2023, it stands as a critical resource for those seeking to stay at the forefront of the field, currently positioned at rank #29 out of 208 according to Scopus metrics, placing it in the 86th percentile. The journal's commitment to high-quality peer-reviewed articles fosters an environment of scholarly exchange that is essential for innovation and professional growth in pathology and forensic studies. Researchers and practitioners alike are encouraged to contribute and engage with a community dedicated to excellence in clinical research.

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

Annals of Diagnostic Pathology, published by Elsevier Science Inc, is a pivotal journal in the field of diagnostic pathology that has significantly contributed to the advancement of medical science since its inception in 1997. With an ISSN of 1092-9134 and E-ISSN of 1532-8198, this esteemed journal is positioned within the Q2 category in both Medicine (miscellaneous) and Pathology and Forensic Medicine, reflecting its high-quality research contributions, showcased by its ranking at #73 out of 208 in Scopus for the latter category. The journal's scope encompasses various aspects of diagnostic pathology, from innovative techniques to critical reviews of pathologic findings, making it an essential resource for researchers, medical professionals, and students dedicated to enhancing diagnostic accuracy and patient care. Although it does not currently offer open access options, its wide readership and impactful publications continue to influence clinical practices and research agendas. With a convergence period extending to 2024, Annals of Diagnostic Pathology remains a leading platform for disseminating valuable knowledge in this dynamic field.

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.